2025-02-17
SENOVA to Showcase at CPHI Jap
SENOVA Participates in 2025 Japan CPHI International Pharmaceutical Exhibition to Deepen Collaboration and Explore New Opportunities in Pharmaceutical Intermediates
Release Time: 2025-04-22
News Source: SenovaTech
Author: SENOVA—Lucas
From April 9 to 11, 2025, the global pharmaceutical industry event, CPHI Japan, was grandly held at the Tokyo International Exhibition Center. SENOVA, a leading enterprise in pharmaceutical intermediates, showcased multiple core products and innovative solutions at the exhibition. The company engaged in in-depth exchanges with global industry experts, renowned pharmaceutical companies, and partners to explore new pathways for the future development of the pharmaceutical industry.
Intermediate Products Lead Industry Innovation
At the exhibition, SENOVA highlighted its strengths in intermediate R&D and production. The company’s products, renowned for their exceptional quality and stable performance, attracted numerous international clients for business discussions. SENOVA’s professional team provided detailed explanations of product features, production processes, and quality control systems, offering customized solutions tailored to diverse client needs.
Deepening Client Collaboration for Shared Growth
During the event, SENOVA’s team held meetings with representatives from multiple Japanese pharmaceutical companies. Discussions focused on customized intermediate development, supply chain collaboration, and global market expansion, leading to preliminary agreements on long-term partnerships. These efforts further strengthened SENOVA’s ties with the Japanese market, creating new opportunities for international growth.
Global Vision: Empowering Pharmaceutical Innovation
“CPHI Japan serves as a vital platform for SENOVA to deepen its international market presence,” the company emphasized. “Moving forward, we will leverage technological advancements and global strategies to deliver more efficient and sustainable intermediate solutions, driving high-quality development in the pharmaceutical industry.”
